Background {#Sec1}
==========

Acute myeloid leukemia (AML) is primarily a disease of the elderly, with a median age at diagnosis of 68--72 years \[[@CR1]\]. For these patients, prognosis still remains very poor. Recent data indicate a median survival of 3 months for patients \> 65 years, with slightly higher estimates for patients aged 66--75 years (about \~ 6 months) than in patients 76--89 year olds (in the neighborhood of 2.5 months) and merely 5% of the patients are alive 5 years from diagnosis \[[@CR2]\].

In elderly, AML is associated with poorer prognosis than in the younger, due to the frequent adverse genetic or epigenetic features present at diagnosis and the increased non-relapse mortality (NRM) \[[@CR3]\]. Although most elderly AML patients still succumb to their disease, improvements in the prognosis have been documented in recent years, due to better supportive care, management of infections, and patient selection for chemotherapy based on comorbidity scores \[[@CR4]\]. Allogenic stem cell transplantation (allo-SCT) remains the most effective anti-leukemic treatment in AML, but the toxicity of the procedure and the difficulty to allocate a suitable donor have limited allo-SCT to a small fraction of patients in need \[[@CR5]\]. Both the development of reduced conditioning regimens (RIC) \[[@CR6]--[@CR8]\] and the use of alternative donors improved the accessibility to transplant for high-risk patients in need. Indeed, a recent study reports that over the past decade, utilization and survival after allo-SCT have significantly increased in patients ≥ 70 years \[[@CR9]\].

Availability of a donor for this high-risk patient population is still a challenge. HLA matched related donor (MRD) transplants remain the best choice for optimal transplant outcome, but only approximately 25--30% of patients have such a donor \[[@CR10]\]. Moreover, in the elderly patients, availability of MRD is even lower, due to the increased age of family members as well as comorbidities and contraindications for stem cell donation. Other donor options include HLA-matched unrelated donors (MUD), HLA-mismatched unrelated donors 9/10 (MMUD), umbilical cord blood units (UCB), and haploidentical family donors. MUD or MMUD are frequently used when a suitable MRD is lacking, with similar transplantation outcomes \[[@CR11]--[@CR14]\]. However, these reports focus mainly on young patients receiving myeloablative conditioning (MAC), and there are only few data from older populations \[[@CR15]\]. In the absence of MRD, MUD is one of the possible choices but the probability to find a donor is estimated to be around 75% in Caucasians, 46% in Middle East or North African origin, and only 16% in African-Americans \[[@CR16]\]. In addition, the search may take few weeks or even months while waiting for a volunteer donor; the leukemia may reoccur.

Over the last recent years, haploidentical donors have been increasingly used as a valid alternative for allo-SCT \[[@CR17]\]. Unmanipulated haploidentical transplant (Haplo-SCT) without T-cell depletion (TCD) is currently used more frequently either with anti-thymocyte globulins (ATG) or post-transplant cyclophosphamide (PT-Cy) as graft versus host disease (GVHD) prophylaxis \[[@CR18]--[@CR20]\]. The optimization of conditioning regimens has further extended the use of Haplo-SCT to older patients and those with significant pre-transplant comorbidities. However, while the feasibility of allo-SCT from an MRD using reduced intensity conditioning (RIC) regimens in elderly patients was demonstrated in several studies \[[@CR21]--[@CR23]\], only few studies reported the outcomes of Haplo-SCT in elderly patients mainly using RIC and PT-Cy-based GVHD prophylaxis \[[@CR24]--[@CR29]\].

With the aim to better define the role of alternative donors in elderly patients with AML, we performed a large registry-based study, with the European Society of Bone Marrow Transplantation (EBMT)-Acute Leukemia Working Party (ALWP), comparing non-TCD Haplo-SCT to transplants from MUD for AML patients 60 years and older.

Methods {#Sec2}
=======

Study design and definition {#Sec3}
---------------------------

This is a retrospective registry-based analysis on behalf of the ALWP of EBMT. The EBMT is a non-profit, scientific society representing more than 600 transplant centers mainly in Europe that are required to report all consecutive stem cell transplantations and follow-ups once a year. Data are entered, managed, and maintained in a central database with internet access; each EBMT center is represented in this database. Audits are routinely performed to determine the accuracy of the data. Patients provide informed consent authorizing the use of their personal information for research purposes.

Eligibility criteria included all adults ≥ 60 years with AML, who underwent a first allo-SCT between January 2007 and December 2014, using either a 10/10 MUD or Haplo from a family donor (recipient-donor number of mismatches ≥ 2). Transplants were performed in 210 EBMT centers.

MAC was defined as a regimen containing either total body irradiation (TBI) with a dose greater than 6 Gy, a total dose of oral busulfan (Bu) greater than 8 mg/kg, or a total dose of intravenous Bu greater than 6.4 mg/kg or melphalan at doses \> 140 mg/m^2^. In addition, regimens containing two alkylating agents were considered as MAC. All other regimens were defined as RIC \[[@CR30]\]. Cytogenetics abnormalities were classified according to the 2010 European Leukemia Net cytogenetic classification system \[[@CR31]\].

Endpoints {#Sec4}
---------

The primary endpoint was leukemia-free survival (LFS). Secondary endpoints were overall survival (OS), refined graft-versus-host-free, relapse-free survival (GRFS), neutrophil engraftment, acute (a)GVHD and chronic (c)GVHD, relapse incidence (RI), and non-relapse mortality (NRM). LFS was defined as the interval from Haplo-SCT to either relapse or death in remission. OS was defined as the time to death from all causes. GRFS events have been defined as grade III--IV aGVHD, severe cGVHD, disease relapse, or death from any cause after SCT \[[@CR32]\]. Engraftment was defined as the first of three consecutive days with an absolute neutrophil count \> 0.5 × 10^9^/l. aGVHD was graded according to the modified Glucksberg criteria \[[@CR33]\] and cGVHD according to the revised Seattle criteria \[[@CR34]\].

Statistical analysis {#Sec5}
--------------------

Patient-, disease-, and transplant-related variables were compared between the two groups (Haplo or MUD) using the chi-square statistic for categorical variables and the Mann-Whitney test for continuous variables. Factors that differ significantly between the two groups with *p* values of \< 0.05 and all factors known as potential prognostic factors were included in the final models. Cumulative incidence (CI) of relapse and NRM was calculated from the date of transplant to the date of relapse or death in remission, respectively, with the other event being the competing risk. For studying GVHD, both relapse and death were considered as competing events. Univariate comparisons of time-dependent endpoints were done using the log-rank test for OS and LFS and GRFS and the Gray's test for cumulative incidence functions. A multivariate analysis was performed using Cox proportional hazards model. Variables were included in the multivariate model if they were conceptually important or if they approached or attained statistical significance by univariate analysis. All tests are two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event. In order to test for a center effect, we introduced a random effect or frailty for each center into the model. Statistical analyses were performed with the SPSS 22 (SPSS Inc./IBM, Armonk, NY, USA) and R 3.2.3 (R Development Core Team, Vienna, Austria) software package.

To allow for potential confounding factors between treatments that could influence outcome, propensity score matching was also performed \[[@CR35]\]. The following factors were included in the propensity score model: patient age, year of transplant, cytogenetics, status at transplant (Tx), sex, female donor to male recipient vs other combinations, Karnofsky performance status less or more than 90%, patient and donor CMV serology, stem cell source (peripheral blood stem cell (PBSC) vs BM), use of in vivo T-cell depletion, conditioning (MAC vs RIC), and previous autograft. Owing to the significant differences in baseline characteristics between the haplo and MUD groups, caliper matching was fixed to 0.2. The purpose of the propensity score matching strategy was to reduce confounding effects of these variables and strengthen causal inferences. Propensity score analysis was performed using the "MatchIt" (<https://cran.r-project.org/web/packages/MatchIt/index.html>). Comparisons between the two match-paired groups were stratified on matching group.

Results {#Sec6}
=======

Patients, disease, and transplant characteristics {#Sec7}
-------------------------------------------------

We analyzed 250 AML patients ≥ 60 years, receiving Haplo-SCT and 2589 patients transplanted from MUD between 2007 and 2014. Patients and transplant characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Patients and donors characteristicsHaploMUD 10/10*p* valueNumber2502589Follow-up23.18 (1.8--93.9)23.02 (0.2--128)Year of Tx2013 (2006--2014)2012(2001--2014)\< 10^− 4^Time to Tx (months)9 (5.1--18.7)6.8 (4.6--15)0.001Patient sex Male156 (62%)1471 (57%)0.093 Female94 (38%)1114 (43%) Missing04Performance status KPS ≤ 9097 (41%)723 (28%)0.001 KPS ≥ 90139 (59%)1670 (65%) Missing14 (0%)196 (7%)Age65(62.3--66.9)64.8(62.2--67.6)0.756Disease status CR195 (38%)1377 (53%)\< 10^−4^ CR ≥ 246 (18%)436 (17%) Active disease109 (44%)776 (30%) Missing00Cytogenetics Good17 (10%)77 (5%)0.036 Intermediate28 (17%)210 (15%) Poor31 (18%)221 (16%) Secondary AML92 (55%)902 (64%)0.535 Missing821179Previous autologus Tx21 (8%)49 (2%)\< 10^−4^Sex mismatch D/R No F-\>M197 (79%)2210 (88%)\< 10^− 4^ F-\>M53 (21%)297 (12%) Missing082*Abbreviations*: *Haplo* haploidentical; *MUD*, matched unrelated donor; *TX*, transplant; *KPS*, Karnofsky performance status; *CR*, complete remission; *AML*, acute myeloid leukemia; *F*, female; *M*, male; *D*, donor; *R*, recipient

Median follow-up was 23 months for both Haplo and MUD. Haplo-SCT were performed more recently, median year of transplant 2013 vs 2012 for MUD, respectively (*p* \< 10^−4^). Median time from diagnosis to transplant was longer for Haplo (9 vs 6.8 months, respectively, *p* = 0.001). The majority of patients had a Karnofsky performance status (KPS) ≥ 90%, being 59% for Haplo and 70% for MUD, *p* = 0.001. The median age was 65 years (range 60--78) for both groups. Disease status was significantly different between the two groups (*p* \< 10^−4^). Secondary AML was diagnosed in 37% of haplo and 35% of MUD. As for cytogenetics, it was intermediate risk in 17% of Haplo and 15% of MUD, while 18 and 16% of the Haplo and MUD harbor poor-risk cytogenetics, respectively (*p* = 0.03).

Stem cell source, GVHD prophylaxis, and conditioning regimens are provided in Table [2](#Tab2){ref-type="table"}.Table 2Stem cell source, GVHD prophylaxis, and conditioning regimensHaplo, *n* (%)MUD 10/10, *n* (%)*p* valueStem cell source BM129 (52)167 (6)\< 10^−4^ PBSC121 (48)2422 (94) Missing00GVHD prophylaxis Csa based4 (2)426 (17)\< 10^−4^ Csa + Mtx9 (4)656 (26) Csa + Mmf ± others12 (5)1123 (44) CSA + MMF ± MTX16 (7)29 (1) Tacro alone1 (0)20 (1) Mmf + Tacro/Mmf + Siro38 (16)185 (7) Mtx + Tacro0 (0)44 (2) Pt-Cy based156 (65)22 (1) Others14 (1)84 (1)In vivo TCD No181 (74)648 (25)\< 10^−4^ Yes63 (26)1915 (75) Missing626Conditioning regimensMAC66 (27)591 (23)0.238 Bu-Cy/BuFlu7253 TBF318 Flu-Mel781 TBI based461 Other17188RIC182 (73)1948 (77) Bu-Flu10635 TBF5519 Flu-Mel9414 TBI based55457 Other53423*Abbrevations*: *Haplo*, haploidentical; *MUD*, matched unrelated donor; *BM*, bone marrow; *PBSC*, peripheral blood stem cell; *GVHD*, graft versus host disease; *CSA*, cyclosporine; *MTX*, methotrexate; *MMF*, mycophenolate; *TACRO*, tacrolimus; *SIRO*, sirolimus; *PTCY*, post-transplant cyclophosphamide; *TCD*, T-cell depletion; *MAC*, myeloablative conditioning; *BU*, busulphan, *CY*, cyclophosphamide; *FLU*, fludarabine; *TBF*, thiotepa busulphan fludarabine; *MEL*, melphalan; *TREO*, treosulphan; *FLAMSA*, fludarabine, amsacrine, and cytarabine; *TBI*, total body irradiation; *RIC*, reduced intensity conditioning

Stem cell source was the bone marrow (BM) in 52% of Haplo and 6% of MUD. Most of the MUD (94%) received PBSC grafts (p \< 10^−4^). Cyclosporine and mycophenolate were used as the main GVHD prophylaxis in the MUD group (44.5%) while PT-CY for GVHD prophylaxis was used in 65% of Haplo. Finally, T-cell depletion with ATG significantly differs between the two groups (74 vs 26%, respectively, *p* \< 10^−4^) (Table [2](#Tab2){ref-type="table"}). In order to overcome these differences, the propensity score technique was applied and we were able to match 225 haplo with 450 MUD using propensity score matching.

Engraftment and acute and chronic graft versus host disease {#Sec8}
-----------------------------------------------------------

The 60 days CI of neutrophil engraftment was 90% for the Haplo and 97% for the MUD (*p* \< 10^−4^).

In the multivariate analysis (Table [3](#Tab3){ref-type="table"}), the risk of grade II--IV aGVHD (HR 1.17, *p* = 0.37, 95% CI 0.82--1.65) and cGVHD (HR1.21, *p* = 0.28, 95% CI 0.84--1.75) was not associated to the type of donor. However, recipients of MUD experienced higher risk of extensive cGVHD compared to Haplo (HR 2, *p* = 0.01, 95% CI 1.17--3.47).Table 3Multivariate analysisHRCI*p*LFS MUD vs Haplo0.940.76--1.170.630 Year of Tx1.010.98--1.030.445 Age (per 10 years)1.100.95--1.270.173 Status at Tx  CR ≥ 2 vs CR11.221.05--1.420.009  Advanced vs CR11.671.48--1.89\< 10^− 4^ Cytogenetics  Intermediate vs good1.100.76--1.600.590  Poor vs good1.791.25--2.560.001  Secondary vs good1.491.06--2.080.019  Missing vs good1.401.01--1.950.043 Female D/male R1.090.93--1.270.247 KPS ≥ 90%0.850.76--0.960.009 PBSC vs BM1.040.86--1.250.670 In vivo TCD0.930.82--1.050.288 Previous autograft1.361.00--1.860.045 RIC vs MAC1.040.92--1.180.468 Center (frailty)0.292OS MUD vs Haplo0.870.68--1.100.244 Year of Tx1.010.98--1.040.392 Age (per 10 years)1.161.00--1.340.046 Status at Tx  CR ≥ 2 vs CR11.160.99--1.370.059  Advanced vs CR11.621.42--1.85\< 10^−4^ Cytogenetics  Intermediate vs good1.050.71--1.540.792  Poor vs good1.661.14--2.400.007  Secondary vs good1.400.99--1.980.057  Missing vs good1.320.94--1.870.105 Female D/male R1.140.97--1.340.093 KPS ≥ 90%0.830.74--0.940.003 PBSC vs BM1.010.83--1.240.893 in vivo TCD0.930.81--1.080.372 Previous autograft1.391.00--1.930.043 RIC vs MAC1.120.97--1.280.096 Center (frailty)0.062RI MUD vs Haplo1.060.76--1.470.699 Year of Tx0.990.96--1.030.790 Age (per 10 years)0.870.71--1.080.230 Status at Tx  CR ≥ 2 vs CR11.261.01--1.570.033  Advanced vs CR11.961.65--2.34\< 10^−4^ Cytogenetics  Intermediate vs good0.950.57--1.600.869  Poor vs good2.111.29--3.430.002  Secondary vs good1.350.85--2.140.202  Missing vs good1.310.83--2.060.241 Female D/male R0.880.69--1.110.285 KPS ≥ 90%0.960.82--1.140.711 PBSC vs BM1.020.77--1.340.865 in vivo TCD1.040.86--1.250.662 Previous autograft1.160.71--1.880.546 RIC vs MAC0.910.76--1.100.374 Center (frailty)0.135NRM MUD vs Haplo0.750.54--1.050.095 Year of Tx1.020.98--1.060.243 Age (per 10 years)1.341.10--1.630.003 Status at Tx  CR ≥ 2 vs CR11.180.94--1.470.135  Advanced vs CR11.451.21--1.74\< 10^−4^ Cytogenetics  Intermediate vs good1.290.75--2.220.353  Poor vs good1.460.84--2.510.172  Secondary vs good1.630.99--2.680.051  Missing vs good1.490.91--2.430.111 Female D/male R1.341.08--1.650.005 KPS ≥ 90%0.750.63--0.890.001 PBSC vs BM1.080.82--1.430.564 In vivo TCD0.850.70--1.040.122 Previous autograft1.621.07--2.460.022 RIC vs MAC1.190.98--1.430.066 Center (frailty)0.015GRFS MUD vs Haplo1.180.95--1.470.125 Year of Tx0.990.97--1.020.792 Age (per 10 years)1.030.90--1.180.606 Status at Tx  CR ≥ 2 vs CR11.161.00--1.340.038  Advanced vs CR11.641.45--1.84\< 10^−4^ Cytogenetics  Intermediate vs good1.240.87--1.750.223  Poor vs good1.691.20--2.380.002  Secondary vs good1.521.11--2.090.008  Missing vs good1.451.06--1.980.019 Female D/male R1.050.90--1.210.516 KPS ≥ 90%0.850.76--0.940.003 PBSC vs BM1.090.91--1.320.313 In vivo TCD0.750.66--0.85\< 10^−4^ Previous autograft1.320.97--1.800.072 RIC vs MAC1.000.88--1.130.933 Center (frailty)0.093aGVHD II--IV MUD vs Haplo1.170.82--1.650.374 Year of Tx1.000.96--1.040.845 Age (per 10 years)0.890.71--1.110.326 Status at Tx  CR ≥ 2 vs CR11.000.79--1.270.942  advanced vs CR11.150.95--1.400.135 Cytogenetics  Intermediate vs good1.340.77--2.340.296  Poor vs good1.450.83--2.530.180  Secondary vs good1.400.84--2.340.192  Missing vs good1.300.78--2.160.303 Female D/male R1.100.88--1.390.378 KPS ≥ 90%0.870.73--1.050.152 PBSC vs BM1.010.75--1.350.954 In vivo TCD0.700.57--0.850.001 Previous autograft2.181.42--3.36\< 10^−4^ RIC vs MAC1.020.82--1.250.853 Center (frailty)0.011aGVHD III--IV MUD vs Haplo1.520.85--2.710.154 Year of Tx0.970.91--1.030.369 Age (per 10 years)0.980.68--1.410.935 Status at Tx  CR ≥ 2 vs CR11.230.83--1.840.290  Advanced vs CR11.781.31--2.43\< 10^−4^ Cytogenetics  Intermediate vs good2.270.77--6.680.133  Poor vs good1.670.55--5.040.361  Secondary vs good2.030.73--5.670.173  Missing vs good1.690.61--4.700.311 Female D/male R1.020.69--1.510.895 KPS ≥ 90%0.680.52--0.910.009 PBSC vs BM1.200.71--2.020.478 In vivo TCD0.630.46--0.860.004 Previous autograft2.071.03--4.150.039 RIC vs MAC0.760.53--1.090.147 Center (frailty)0.054cGVHD MUD vs Haplo1.220.84--1.750.281 Year of Tx0.970.94--1.010.228 Age (per 10 years)0.990.80--1.230.964 Status at Tx  CR ≥ 2 vs CR11.050.84--1.300.669  Advanced vs CR11.120.92--1.370.251 Cytogenetics  Intermediate vs good1.721.01--2.910.042  Poor vs good1.741.01--2.990.045  Secondary vs good1.881.14--3.100.013  Missing vs good1.661.01--2.720.043 Female D/male R1.020.81--1.280.860 KPS ≥ 90%1.090.91--1.310.310 PBSC vs BM1.481.08--2.030.013 In vivo TCD0.570.47--0.70\< 10^−4^ Previous autograft1.640.99--2.700.050 RIC vs MAC0.820.67--1.020.077 Center (frailty)0.001Extensive cGVHD MUD vs Haplo2.021.17--3.470.011 Year of Tx0.970.92--1.020.298 Age (per 10 years)1.050.77--1.420.740 Status at Tx  CR ≥ 2 vs CR10.920.67--1.260.618  Advanced vs CR10.970.73--1.300.874 Cytogenetics  Intermediate vs good1.150.56--2.370.693  Poor vs good1.390.67--2.900.371  Secondary vs good1.270.64--2.490.481  Missing vs good1.110.57--2.160.751 Female D/male R0.940.66--1.340.751 KPS ≥ 90%1.000.77--1.290.997 PBSC vs BM1.300.83--2.050.245 In vivo TCD0.350.27--0.46\< 10^−4^ Previous autograft1.190.54--2.600.658 RIC vs MAC0.740.54--1.010.060 Center(frailty)0.022*Abbreviations*: *LFS*, leukemia-free survival; *OS*, overall survival; *RI*, relapse incidence; *NRM*, non-relapse mortality; *GRFS*, graft-versus-host-free-relapse free survival; *a*, acute; *c*, chronic; *GVHD*, graft versus host disease; *MUD*, matched unrelated donor; *Haplo*, haploidentical; *Tx*, transplant; *CR*, complete remission; *KPS*, Karnofsky performance status; *PBSC*, peripheral blood; *BM*, bone marrow; *D*, donor; *R*, recipient; *TCD*, T cell depletion; *RIC*, reduced intensity conditioning; *MAC*, myeloablative conditioning

In vivo T-cell depletion was associated with a reduced risk of aGVHD (HR 0.699, 95% CI 0.57--0.858, *p* \< 0.01) and cGVHD (HR 0.57, 95% CI 0.4--0.7, *p* \< 0.01) while the use of PBSC as stem cell source increased risk of cGVHD (HR 1.48, 95% CI 1.08--2.03, *p* = 0.01).

These findings were confirmed in the pair-matched analysis, with a significantly increased risk of extensive cGVHD (20.5 vs 10.7%, *p* = 0.0041) in MUD vs Haplo (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1**a**) cGVHD; **b**) extensive cGVHD after MUD and Haplo SCT in AML patients ≥ 60 years after matched pair analysis

Relapse incidence and NRM {#Sec9}
-------------------------

In multivariate analysis (Table [3](#Tab3){ref-type="table"}), there was no difference in RI according to the type of donor. Factors independently associated with increased risk of relapse were disease status at transplantation (HR 1.96, 95% CI 1.65--2.34, *p* \< 0.01) and cytogenetics risk (poor vs good) (*p* = 0.002) (Table [3](#Tab3){ref-type="table"}).

The most common causes of death were disease recurrence (35% in the haplo and 45% in the MUD group, respectively), infections (35 vs 26%), and GVHD (18 vs 16%).

In multivariate analysis, the type of donor did not influence the risk of NRM. Increased age (HR 1.342, *p* = 0.003, 95% CI 1.102--1.634), KPS (HR 0.753, 95% CI 0.637--0.891, *p* = 0.0009), and advanced disease status (HR 1.454, 95% CI 1.212--1.743, *p* \< 10^−4^) (Table [3](#Tab3){ref-type="table"}) were the factors independently associated with increase in mortality. These results were confirmed in the pair-matched analysis (Table [4](#Tab4){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}a, b).Table 4Propensity score analysis for LFS, OS, RI, NRM, GRFS, aGVHD II--IV, aGVHD III--IV, cGVHD, and ext. cGVHDMUDHaplo*p* valueLFS39.9% \[34.7--45.1\]34.6% \[27.9--41.3\]0.67OS42% \[36.7--47.4\]38.7% \[31.8--45.5\]0.33RI31.9% \[27.2--36.7\]27.7% \[21.7--34\]0.17NRM28.2% \[23.6--32.9\]37.7% \[31.1--44.3\]0.06GRFS24.8% \[20.3--29.4\]30.2% \[23.7--36.6\]0.15aGVHD II-IV33.1% \[28.6--37.6\]30.5% \[24.4--36.8\]0.28cGVHD40.6% \[35.3--45.9\]26.5% \[20.5--32.7\]0.24ext cGVHD20.5% \[16.2--25.1\]10.7% \[6.8--15.5\]0.041*Abbreviations*: *LFS*, leukemia free survival; *OS*, overall survival; *RI*, relapse incidence; *NRM*, non-relapse mortality; *GRFS*, graft-versus-host-free-relapse free survival; *a*, acute; *c*, chronic; *GVHD*, graft versus host disease; *ext.*, extensiveFig. 2**a**) RI; **b**) NRM; **c**) LFS; **d**) OS after MUD and Haplo SCT in AML patients ≥ 60 years after matched pair analysis

OS, LFS, and GRFS {#Sec10}
-----------------

The median follow-up for survivors was 23 months. In adjusted multivariate analysis, OS (HR1.18, CI 0.686--1.102, *p* = 0.2481), LFS (HR 0.94, CI 0.767--1.174, *p* = 0.63), and GRFS (HR1.18, CI 0.954--1.47, *p* = 0.125) (Table [3](#Tab3){ref-type="table"}) were comparable according to the type of donor. These results were confirmed in the pair-matched population (Table [4](#Tab4){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}c, d). Other independent factors influencing LFS, OS, and GRFS were disease status at transplantation (HR 1.67, 95% CI 1.48--1.89, *p* \< 0.01; HR 1.62, 95% CI 1.42--1.85, *p* \< 0.01; HR 1.64, 95% CI 1.45--1.84, *p* \< 0.01), cytogenetic risk (HR 1.79, 95% CI 1.25--2.56, *p* \< 0.01; HR 1.66, 95% CI 1.14--2.40, *p* \< 0.01; HR 1.69, 95% CI 1.20--2.38, *p* \< 0.01), KPS (HR 0.85, 95% CI 0.76--0.96, *p* = 0.009; HR 0.83, 95% CI 0.74--0.94, *p* = 0.003; HR 0.85, 95% CI 0.76--0.94, *p* = 0.003). Previous autograft was associated with lower OS (HR 1.39, 95% CI 1.00--1.93, *p* = 0.04) and LFS (HR 1.36, 95% CI 1.00--1.86, *p* = 0.04). Importantly, OS was also influenced by incremental age (HR 1.16, 95% CI 1.00--1.34, *p* = 0.04).

Discussion {#Sec11}
==========

AML incidence increased with age and picked at the sixth--seventh decade of life; it is thus a disease of the elderly, and often at diagnosis, it is highly aggressive in this group of patients. Allo-SCT offers the best curative option with curative potential for these patients, despite the higher risk of complications related to transplant at advanced age as a result of frequent comorbidities and reduced compatible sibling donor availability at this age. Several studies demonstrated the feasibility of allo-SCT with the use of RIC in older population \[[@CR6]--[@CR8]\]. Recently, Rashidi et al. \[[@CR36]\] reported 35 and 38% of 3 years LFS and OS, respectively, for elderly AML patients. With the development of new transplant techniques making alternative donors more realistic clinical option, when a MRD donor is not available, the question of which is the best alternative donor and the alternative donor hierarchy is still unanswered. MUD is known to have comparable outcomes to MRD allo-SCT \[[@CR11]--[@CR14]\], but it has the major disadvantage of rather long time for donor identification. On the other hand, Haplo-SCT is increasing worldwide, and it has the main advantage of providing a timely transplant thanks to rapid donor identification for almost all patients in need.

In the present study, we compared the results of allo-SCT from Haplo donors or MUD 10/10 in a large number of AML patients ≥ 60 years, in an attempt to better understand which is the best transplant choice in this setting.

Weisdorf et al. \[[@CR37]\], evaluated the role of alternative donors in 740 older AML patients, but only 29 cases of Haplo-SCT were included in the study precluding a comparison for this type of donor.

Chen et al. using ATG based GVHD prophylaxis reported similar outcomes of myeloablative haploidentical SCT in patients aged ≥50 years in comparison to younger adults (24). The same group also confirmed the efficacy of unmanipulated haplo-SCT compared to unrelated donors in young adult with hematological malignancies (25). The feasibility of Haplo-SCT with PT-Cy in the older patients was retrospectively analyzed by Kasamon et al. \[[@CR26]\] in 271 patients with hematological malignancies (AML 24%) receiving a RIC regimen with fludarabine, cyclophosphamide, and low dose of TBI. For AML patients aged \> 60 years, the 3 years LFS, RI, and OS were 31, 60, and 38%, respectively. These results are in line with ours, especially in terms of OS and LFS, despite the fact that in our analysis, being a registry-based study, we included different conditioning regimes and GVHD prophylaxis. Importantly, given the different type of GVHD prophylaxis in the haplo group, we performed a subgroup analysis according to the use or not of PT-Cy, comparing those two groups vs MUD. Our results confirm the decreased risk of extensive cGVHD for haplo recipients both in the group of PT-Cy and MUD, as well in the group of Haplo with an ATG-based GVHD prophylaxis (without PT-Cy) vs MUD.

In our population, age at transplant was an independent factor associated with reduced OS. Slade et al. \[[@CR28]\] recently, retrospectively analyzed the impact of age on Haplo-SCT with PT-Cy and PBSC for AML or myelodysplastic syndrome (MDS), showing a detrimental effect of older age, in accordance with our results.

In a single center study, Blaise et al. \[[@CR27]\] recently reported a comparison of outcome of patients older than 55 years receiving Haplo-SCT with PT-Cy, with those receiving MRD or MUD. Despite the low number of patients with AML reported (30%), the results of this study showed that tolerability and efficacy of Haplo-SCT is equivalent to that of MRD and better than MUD. In our population, we did not find difference in OS, LFS, RI, and NRM, between transplantation from Haplo and MUD beside a difference in cGVHD. MUD is associated with higher incidence of cGVHD also when compared with MRD \[[@CR38]\]. This could be explained by an effect of minor HLA mismatch and also by the increased use of PBSC in the MUD group, which is an important factor also reported by others \[[@CR39]\]. Importantly, the application of PT-Cy as GVHD prophylaxis in the unrelated donor setting is attractive, and some encouraging results are reported \[[@CR40]\]. Lastly, Ciurea et al. \[[@CR29]\] recently analyzed 43 patients with AML/MDS (median age 61 years) who underwent a Haplo-SCT using PT- Cy. Factors that positively influenced LFS were intermediate/good risk cytogenetics in the first or second remission and younger donors (\< 40 years). These results are similar to ours, despite we included different platforms of Haplo-SCT in the current series. Importantly, in our study disease status was one of the main factors associated with outcomes. Using the propensity score analysis, we performed a separate analysis according to disease status, confirming the main results and the reduced risk of cGVHD for patients receiving haploidentical transplant in CR1.

We are aware that our study has some limitations related to its retrospective nature. Importantly, the conditioning regimen and the GVHD prophylaxis are heterogeneous, and thus, we were unable to define a specific drug combination in this particular population of patients.

In order to address the difference in number among the two groups, a propensity score analysis was performed which confirmed the same findings.

Conclusions {#Sec12}
===========

Given our results, we confirm that Haplo-SCT is a valid option in fit AML patients ≥ 60 years, especially in patients in first complete remission, with intermediate/high cytogenetic risk. The rapid availability of Haplo donor and the possible use in further strategies of immunotherapy make this donor source very attractive for high-risk patients. A prospective clinical trial ([ClinicalTrials.gov](http://clinicaltrials.gov) Identifier NCT02623309) comparing Haplo vs MUD in elderly patients without MRD is ongoing to address efficacy, safety, and the evaluation of quality of life. The results of this trial could help in clarifying the role of alternative donors in the elderly, to provide better cure in this high-risk population.
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:   Acute Leukemia Working Party
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GRFS
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GVHD

:   Graft versus host disease
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:   Haploidentical transplant
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LFS
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:   Myeloablative conditioning
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:   Myelodysplastic syndrome

MMUD

:   Mismatched unrelated donors
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:   Matched related donor
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:   Overall survival
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:   Peripheral blood stem cell

PT-Cy
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:   Relapse incidence
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:   Total body irradiation
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:   Transplant
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